Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-HC01 in Advanced Biliary Tract Cancers
NCT07641036Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 2 trial of EB-HC01 in cholangiocarcinoma (CCA), biliary tract cancer (BTC), gallbladder carcinoma, sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EB-HC01
03
Conditions
cholangiocarcinoma (CCA)biliary tract cancer (BTC)gallbladder carcinoma
Beyond the preview
Go deeper on NCT07641036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07641036.